G
NKTR icon

Gainplan’s Nektar Therapeutics NKTR Stock Holding History

Gainplan’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
14,962
+9,962
+199% +$729K 0.41% 31
2026
Q1 		$360K Sell
5,000
-8,500
-63% -$484K 0.27% 39
2025
Q4 		$571K Buy
13,500
+8,465
+168% +$474K 0.21% 33
2025
Q3 		$286K Sell
5,035
-9,965
-66% -$330K 0.12% 45
2025
Q2 		$388K Buy
+15,000
New +$168K 0.18% 39

Other funds holding NKTR

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return

Gainplan's NKTR Position: Q2 2026 in Review

Gainplan increased its Nektar Therapeutics (NKTR) stake by 199% in Q2 2026, buying an estimated $729K and bringing the position to 14,962 shares worth $1.04M. The position accounts for 0.41% of the portfolio, ranked #31.

Gainplan first reported a position in NKTR in Q2 2025 and has held it in 5 quarters since. 11 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Gainplan held 14,962 shares of Nektar Therapeutics worth $1.04M as of Q2 2026.
  • Gainplan bought 9,962 Nektar Therapeutics shares in Q2 2026, an estimated $729K.
  • Nektar Therapeutics made up 0.41% of Gainplan's portfolio in Q2 2026, its #31 holding.
  • Gainplan first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 11 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Gainplan's 13F filing for Q2 2026, filed 7 Jul 2026.